Fumihiro Takahashi
5PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Dec 23, 2025
Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.Angela Genge, Jeffrey Rothstein, Shari De Silva
|Jun 06, 2025
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).Jeffrey Rothstein, Angela Genge, Shari De Silva
|Aug 01, 2023
The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis.Benjamin Rix Brooks, Erik P Pioro, Takeshi Sakata
|Sep 02, 2022
Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.Fumihiro Takahashi, Osamu Kano, Yoshito Nagano
|Sep 02, 2022
Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.Fumihiro Takahashi, Osamu Kano, Yoshito Nagano
Pageof 1
